[1] |
Peters C, Brown S . Antibody-drug conjugates as novel anti-cancer chemotherapeutics[J]. Biosci Rep, 2015,35(4):1042-1061.
|
[2] |
Bouchard H, Viskov C, Garcia-Echeverria C . Antibody-drug conjugates: a new wave of cancer drugs[J]. Bioorg Med Chemi Lett, 2014,24(23):5357-5363.
|
[3] |
Hamblett KJ, Senter PD, Chace DF , et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate[J]. Clin Cancer Res, 2004,10(20):7063-7070.
|
[4] |
Wang L, Amphlett G, Blättler WA , et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry[J]. Protein Sci, 2005,14(9):2436-2446.
|
[5] |
Sun MM, Beam KS, Cerveny CG , et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides[J]. Bioconjug Chem, 2005,16(5):1282-1290.
|
[6] |
Junutula JR, Raab H, Clark S , et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index[J]. Nat Biotechnol, 2008,26(8):925-932.
|
[7] |
Tian F, Lu Y, Manibusan A , et al. A general approach to site-specific antibody drug conjugates[J]. Proc Natl Acad Sci USA, 2014,111(5):1766-1771.
|
[8] |
Li X, Yang J, Rader C . Antibody conjugation via one and two C-terminal selenocysteines[J]. Methods, 2013,65(1):133-138.
|
[9] |
Tang F, Yang Y, Tang Y , et al. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates[J]. Org Biomol Chem, 2016,14(40):9501-9518.
|
[10] |
Dennler P, Fischer E, Schibli R . Antibody conjugates: from heterogeneous populations to defined reagents[J]. Antibodies, 2015,4(3):197-224.
|
[11] |
Shen BQ, Xu K, Liu L , et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates[J]. Nat Biotechnol, 2012,30(2):184-189.
|
[12] |
Wang L, Brock A, Schultz PG , et al. Expanding the genetic code of Escherichia coli[J]. Science, 2001,292(5516):498-500.
|
[13] |
Slamon DJ, Leyland-Jones B, Shak B , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001,344(11):783-792.
|
[14] |
Meden H, Kuhn W . Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor[J]. Eur J Obstet Gynecol Reprod Biol, 1997,71(2):173-179.
|
[15] |
Al-toub M, Vishnubalaji R, Hamam R , et al. CDH1 and IL1-beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and human mesenchymal stem cells[J]. Stem Cell Res Ther, 2015,6(1):135.
|
[16] |
Yang J, Yang G, Hou G , et al. Scutellaria barbata D. Don polysaccharides inhibit the growth of Calu-3 xenograft tumors via suppression of the HER2 pathway and angiogenesis[J]. Oncol Lett, 2015,9(6):2721-2725.
|
[17] |
Nonagase Y, Yonesaka K, Kawakami H , et al. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1[J]. Oncotarget, 2016,7(51):84860-84871.
|
[18] |
de Vlieghere E, Carlier C, Ceelen W , et al. Data on in vivo selection of SK-OV-3 luc ovarian cancer cells and intraperitoneal tumor formation with low inoculation numbers[J]. Data Brief, 2016,6:542-549.
|
[19] |
Atnip AA, Sigurdson GT, Bomser J , et al. Time, concentration, and pH-dependent transport and uptake of anthocyanins in a human gastric epithelial (NCI-N87) cell line[J]. Int J Mol Sci, 2017,18(2):446.
|
[20] |
Trail PA, Dubowchik GM, Lowinger TB . Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design[J]. Pharmacol Ther, 2018,181:126-142.
|
[21] |
Behrens CR, Liu B . Methods for site-specific drug conjugation to antibodies[J]. MAbs, 2014,6(1):46-53.
|
[22] |
Jain N, Smith SW, Ghone S , et al. Current ADC linker chemistry[J]. Pharm Res, 2015,32(11):3526-3540.
|
[23] |
Diamantis N, Banerji U . Antibody-drug conjugates: an emerging class of cancer treatment[J]. Br J Cancer, 2016,114(4):362-367.
|
[24] |
Panowski S, Bhakta S, Raab H , et al. Site-specific antibody drug conjugates for cancer therapy[J]. MAbs, 2014,6(1):34-45.
|
[25] |
Fishkin N, Maloney EK, Chari RV , et al. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions[J]. Chem Commun, 2011,47(38):10752-10754.
|
[26] |
Ponte JF, Sun X, Yoder NC , et al. Understanding how the stabi-lity of the thiol-maleimide linkage impacts the pharmacokinetics of lysine-linked antibody-maytansinoid conjugates[J]. Bioconjug Chem, 2016,27(7):1588-1598.
|